読み込み中
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
前日終値
$8.34
−$0.32 · -3.70%
日中の時刻はETです。市場データは遅延する場合があります。
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
日中レンジ
現在 $8.34
52週レンジ
現在 $8.34
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
14
著しい割高
センチメント
63
強気
リスク
63
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
日中レンジ
現在 $8.34
52週レンジ
現在 $8.34
営業利益
純利益
| 指標（CHF） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 68.6万 CHF | — | — | — |
| 売上原価 | — | 5208.3万 CHF | — | — | — |
| 粗利益 | — | −5139.7万 CHF | — | — | — |
| 研究開発 | 5451.86万 CHF | 5208.3万 CHF | 2924.7万 CHF | 2222.4万 CHF | 956.8万 CHF |
| 販売・一般管理 | 2462.67万 CHF | 2180.7万 CHF | 1472.4万 CHF | 674.3万 CHF | 409.7万 CHF |
| 営業費用 | 7914.54万 CHF | 2180.7万 CHF | 8071.4万 CHF | 3237.6万 CHF | 1323.2万 CHF |
| 受取利息 | 169.04万 CHF | 216.8万 CHF | 159.02万 CHF | 12.6万 CHF | 2.1万 CHF |
| 支払利息 | 79.56万 CHF | 63.9万 CHF | 146.33万 CHF | 644.2万 CHF | 512万 CHF |
| 減価償却費と償却費 | 54.6万 CHF | 40.6万 CHF | 28.7万 CHF | 29.9万 CHF | 23.5万 CHF |
| 営業利益 | −7914.54万 CHF | −7320.4万 CHF | −8071.4万 CHF | −3237.6万 CHF | −1323.2万 CHF |
| 純利益 | −9450.82万 CHF | −8577.7万 CHF | −8880.2万 CHF | −3869.8万 CHF | −1855.2万 CHF |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$36.75
上昇余地（340.65%）この株式へのエクスポージャーを報告している上場投資信託です。
ALPS Medical Breakthroughs ETFSBIO65.25万0.34%1.91億 USD0.50%$55.04+2.03%
Virtus Biotech Clinical Trials ETFBBC24.78万0.60%4099.65万 USD0.65%$44.1456+2.08%
State Street SPDR S&P International Small Cap ETFGWX24.64万0.03%9.08億 USD0.40%$45.56+0.93%
Fidelity Nasdaq Composite Index ETFONEQ21.78万—109.4億 USD0.21%$107.81+0.63%
GlacierShares Nasdaq Iceland ETFGLCR5.93万4.15%142.77万 USD0.95%$23.69+0.77%ALPS Medical Breakthroughs ETFSBIOVirtus Biotech Clinical Trials ETFBBCState Street SPDR S&P International Small Cap ETFGWXFidelity Nasdaq Composite Index ETFONEQGlacierShares Nasdaq Iceland ETFGLCRAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
